سعر كيسكالي 200 مجم 21 قرص 2026

Ribociclib 200 mg film-coated tablets, 21 per pack (Kisqali, Novartis); CDK4/6 kinase inhibitor for HR-positive, HER2-negative breast cancer.

• Adjuvant treatment, with an aromatase inhibitor, of HR-positive, HER2-negative stage II-III early breast cancer at high risk of recurrence (US label).Population: AdultsDailyMed (U.S. National Library of Medicine)
• HR-positive, HER2-negative advanced or metastatic breast cancer with an aromatase inhibitor or fulvestrant (US label).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Early breast cancer (NATALEE): most common adverse reactions (20% or more) including laboratory abnormalities were decreased lymphocytes, leukocytes and neutrophils, decreased haemoglobin, increased ALT and AST, infections, increased creatinine, decreased platelets, headache, nausea and fatigue.International label, same product · DailyMed (U.S. National Library of Medicine)

• None listed in the US label.International label, same product · DailyMed (U.S. National Library of Medicine)

• Interstitial lung disease/pneumonitis, which can be severe or fatal; interrupt for new respiratory symptoms and permanently discontinue for recurrent symptomatic or severe cases.International label, same product · DailyMed (U.S. National Library of Medicine)
• Severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS); permanently discontinue if they occur.International label, same product · DailyMed (U.S. National Library of Medicine)
• Concentration-dependent QT interval prolongation; avoid QT-prolonging drugs and strong CYP3A inhibitors; not indicated with tamoxifen.International label, same product · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A inhibitorsIncrease ribociclib exposure; avoid, or reduce the ribociclib dose if co-administration is unavoidable.DailyMed (U.S. National Library of Medicine)
• QT-prolonging drugs; tamoxifenAdditive QT prolongation; avoid concomitant use (ribociclib is not indicated with tamoxifen).DailyMed (U.S. National Library of Medicine)

• Based on animal findings and its mechanism, ribociclib can cause fetal harm; animal studies showed post-implantation loss, reduced fetal weight and fetal abnormalities; advise pregnant women of the risk.International label, same product · DailyMed (U.S. National Library of Medicine)
• Not known whether ribociclib is present in human milk; it passes readily into rat milk; advise women not to breastfeed during treatment and for at least 3 weeks after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Ribociclib: Inhibits cyclin-dependent kinases 4 and 6; blocking cyclin D-CDK4/6 activity decreases retinoblastoma protein (pRb) phosphorylation, arresting the cell cycle in G1 and reducing proliferation of breast cancer cells.